ClearPoint Neuro, Inc. (CLPT)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 13 | 16 | 21 | 24 | 31 | 37 | 42 | 49 |
| Operating profit | $m | -24 | -31 | ||||||
| Net profit | $m | -7 | -14 | -16 | -22 | -19 | -26 | -35 | -37 |
| EPS reported | $ | -0.90 | -1.18 | ||||||
| Operating cashflow per share | $ | -0.84 | -1.01 | ||||||
| Capex per share | $ | 0.02 | 0.04 | ||||||
| FCF per share | $ | -0.86 | -1.05 | ||||||
| Free cash flow | $m | -24 | -31 | ||||||
| Net debt | $m | 3 | 21 | ||||||
| Book value equity | $m | 28 | 11 | ||||||
| Book value per share | $ | 0.99 | 0.36 | ||||||
| Number of shares | m | 28.32 | 29.86 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 13.82 | 35.95 | ||||||
| P/S LTM | x | 10.48 | 9.16 | ||||||
| P/FCF LTM | x | -15.84 | -12.38 | ||||||
| EV/EBITDA LTM | x | -19.16 | -14.58 | ||||||
| EV/Sales LTM | x | 10.81 | 10.72 | ||||||
| Earnings Yield LTM | % | -6.59% | -8.29% | ||||||
| FCF Yield | % | -6.31% | -8.08% | ||||||
| Quality | |||||||||
| ROE | % | -91.15% | -188.09% | ||||||
| ROIC | % | -27.56% | -40.49% | ||||||
| Operating margin | % | -65.36% | -73.42% | ||||||
| Gross margin | % | +61.38% | +62.61% | ||||||
| FCF/Sales | % | -66.12% | -74.01% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +17.78% | +34.69% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.42 | -0.49 | ||||||
| Net Debt/EBITDA | x | -0.59 | -1.26 | ||||||
| EBIT/Net interest | x | -10.12 | -7.68 | ||||||
| Net debt/market cap | % | +12.67% | +12.04% | ||||||
| Net debt/Equity | x | 0.11 | 1.94 | ||||||
| Gross debt/equity | x | 2.08 | 5.93 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
ClearPoint Neuro, Inc. is a medical technology firm primarily operating within the United States. The company specializes in developing and commercializing sophisticated systems that facilitate minimally invasive brain surgeries, guided by real-time magnetic resonance imaging (MRI) during the procedure. Among its core offerings is the ClearPoint system, designed for the precise placement of deep brain stimulation electrodes, biopsy needles, and for the controlled infusion of medications and laser catheters directly into the brain. It also provides the ClearPoint Neuro Navigation System, which is specifically engineered for MRI suite environments. ClearPoint Neuro maintains strategic partnerships and licensing agreements with prominent institutions and companies, including Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and the University of California, San Francisco. Initially established in 1998 and headquartered in Solana Beach, California, the company operated as MRI Interventions, Inc. before rebranding to ClearPoint Neuro, Inc. in February 2020.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
ClearPoint Neuro, Inc. is a medical technology firm primarily operating within the United States. The company specializes in developing and commercializing sophisticated systems that facilitate minimally invasive brain surgeries, guided by real-time magnetic resonance imaging (MRI) during the procedure. Among its core offerings is the ClearPoint system, designed for the precise placement of deep brain stimulation electrodes, biopsy needles, and for the controlled infusion of medications and laser catheters directly into the brain. It also provides the ClearPoint Neuro Navigation System, which is specifically engineered for MRI suite environments. ClearPoint Neuro maintains strategic partnerships and licensing agreements with prominent institutions and companies, including Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and the University of California, San Francisco. Initially established in 1998 and headquartered in Solana Beach, California, the company operated as MRI Interventions, Inc. before rebranding to ClearPoint Neuro, Inc. in February 2020.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free